Physician profile
Craig J Helm
NPI 1588678791
$4,248.88
in general payments reported to CMS, 2019-2025
27 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $212 · 2021: $725 · 2022: $420 · 2023: $697 · 2024: $831 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.13 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $553.86 | 2023-2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Abbvie INC. | $523.50 | 2023-2025 | |
| Carl Zeiss Meditec USA, INC. | $478.69 | 2021 | |
| Alcon Vision LLC | $455.51 | 2019-2025 | Clareon |
| Johnson & Johnson Vision Care, INC. | $435.36 | 2019 | |
| Sun Pharmaceutical Industries INC. | $255.08 | 2019-2025 | |
| Dompe US, INC. | $221.40 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.54 | 2019-2021 | |
| Allergan, INC. | $160.30 | 2019-2022 | |
| Rxsight INC | $147.68 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $105.21 | 2022-2025 | Scoutpro Osmolarity System, Vyzulta, Envista Mx60 Iol |
| Harrow Eye, LLC | $101.42 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $66.86 | 2019-2020 | |
| Thea Pharma INC. | $62.84 | 2023-2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $60.49 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $59.62 | 2022-2024 | Ryzumvi, Tyrvaya |
| Shire North American Group INC | $59.32 | 2019 | |
| Biotissue Holdings INC. | $57.12 | 2019-2024 | |
| Sight Sciences, INC. | $53.46 | 2022 | |
| Glaukos Corporation | $51.93 | 2022 | |
| Amgen INC. | $41.08 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $32.94 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $27.73 | 2025 | Tecnis Iol, Veritas Vision System |
| Horizon Therapeutics Plc | $18.44 | 2021 | |
| Omeros Corporation | $17.12 | 2019 | |
| Coopervision INC. | $16.90 | 2022 | |
| Tearlab Corp | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.